VXRT

Vaxart Inc

VXRT, USA

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

https://vaxart.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VXRT
stock
VXRT

Vaxart (NASDAQ:VXRT) Stock Passes Below 200-Day Moving Average - Should You Sell? MarketBeat

Read more →
VXRT
stock
VXRT

Targets Report: Why VXRT stock is favored by top institutions - 2025 Price Action Summary & Stepwise Trade Signal Guides moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$3.3333

Analyst Picks

Strong Buy

2

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.17

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-30.43 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-3.90 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

3.42 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

6.81

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 10.12% of the total shares of Vaxart Inc

1.

Vanguard Group Inc

(4.5508%)

since

2025/06/30

2.

Geode Capital Management, LLC

(1.0162%)

since

2025/06/30

3.

BlackRock Inc

(0.7751%)

since

2025/06/30

4.

Marshall Wace Asset Management Ltd

(0.7705%)

since

2025/06/30

5.

State Street Corp

(0.3718%)

since

2025/06/30

6.

UBS Group AG

(0.3607%)

since

2025/06/30

7.

Renaissance Technologies Corp

(0.261%)

since

2025/06/30

8.

Squarepoint Ops LLC

(0.1952%)

since

2025/06/30

9.

Northern Trust Corp

(0.1787%)

since

2025/06/30

10.

Extended Equity Market Fund K

(0.1368%)

since

2025/06/30

11.

Vifag 2002 SICAV

(0.1223%)

since

2025/07/31

12.

Susquehanna International Group, LLP

(0.1016%)

since

2025/06/30

13.

IHT Wealth Management, LLC

(0.1002%)

since

2025/06/30

14.

Royal Bank of Canada

(0.0978%)

since

2025/06/30

15.

NT Ext Equity Mkt Idx Fd - L

(0.0946%)

since

2025/06/30

16.

Northern Trust Extended Eq Market Idx

(0.0946%)

since

2025/06/30

17.

NT Ext Equity Mkt Idx Fd - NL

(0.0794%)

since

2025/06/30

18.

Morgan Stanley - Brokerage Accounts

(0.0791%)

since

2025/06/30

19.

HRT FINANCIAL LLC

(0.0781%)

since

2025/06/30

20.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0718%)

since

2024/12/31

21.

Charles Schwab Investment Management Inc

(0.0672%)

since

2025/06/30

22.

Virtu Financial LLC

(0.0641%)

since

2025/06/30

23.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0616%)

since

2025/06/30

24.

Amvescap Plc.

(0.0519%)

since

2025/06/30

25.

TWO SIGMA SECURITIES, LLC

(0.0471%)

since

2025/06/30

26.

Two Sigma Investments LLC

(0.0467%)

since

2025/06/30

27.

Goldman Sachs Group Inc

(0.0426%)

since

2025/06/30

28.

Goldman Sachs Absolute Ret Trckr Instl

(0.035%)

since

2025/06/30

29.

LUX IM Global Medtech HX

(0.0284%)

since

2025/08/31

30.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0267%)

since

2025/06/30

31.

U.S. Equity Market Fund F

(0.0231%)

since

2025/06/30

32.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0226%)

since

2024/12/31

33.

Extended Equity Market Fund M

(0.0172%)

since

2025/06/30

34.

PGIM Quantitative Solutions US Micro Cap

(0.0126%)

since

2025/06/30

35.

Victory Extended Market Index

(0.0116%)

since

2025/06/30

36.

SSgA U.S. Total Market Index Strategy

(0.0078%)

since

2025/03/31

37.

Dimensional Global Core Equity USD Acc

(0.0077%)

since

2025/06/30

38.

Dimensional Global Small Coms USD Acc

(0.0054%)

since

2025/06/30

39.

Northern Trust Wilshire 5000

(0.0046%)

since

2025/06/30

40.

BNYM Mellon SL Market Completion UC1

(0.0043%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.04

EPS Estimate

-0.0667

EPS Difference

0.0267

Surprise Percent

40.03%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(4.5)
Momentum
No Momentum(3)
Net Net
Possible Net-Net(4)
Quality
Low Quality Business(3)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.